Skip to main content

Table 4 Relative risk for breast cancer associated with the AR-CAG repeat

From: The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer

Author, year [reference]

Population

AR genotype1

Long allele

Cases

Controls

Adjusted for

RR (95% CI)

Rebbeck, 1999 [63]

Multi-institutional study of BRCA1 mutation carriers ascertained through families with a history of breast and/or ovarian cancer between 1978 and 1997

SS

28+ repeats

19

  

1.81 (1.06–3.08)2

  

SL+LL

 

146

   

Spurdle, 1999 [64]

Early onset breast cancer (<40 years) and age matched controls from Australia

SS

21+ repeats

78

71

Age, country of birth, state, education, marital status, number of live births, height, weight1 year ago, age at menarche, oral contraceptive use, family history, estrogen receptor polymorphism, mother's country of birth, father's country of birth

1.4 (0.92–2.15)

  

SL

 

189

138

 

1.4 (0.87–2.26)

  

LL

 

101

75

  

Dunning, 1999 [65]

Cases from East Anglian region of the UK and random controls from the EPIC cohort

SS

23+ repeats

209

160

  
  

SL

 

215

212

 

0.82 (0.62–1.09)

  

LL

 

84

54

 

1.31 (0.87–1.97)

Giguere, 2001 [66]

Incident cases from Quebec city and age and area of residency matched controls

SS3

21+ repeats

17

61

Matched analysis

2.14 (1.22–3.73)

  

SL+LL

 

238

400

  

Kadouri, 2001 [67]

Affected and unaffected BRCA1/2 carriers from two genetics clinics: one in Jerusalem, Israel, and the other in London, UK

SS

28+ repeats

   

BCRA1/2 carriers:

  

SL+LL

    

0.80 (0.44–1.46)

       

Noncarriers:

       

1.27 (0.83–1.96)

Haiman, 2002 [68]

Cases and controls from the Nurses' Health Study and controls matched on year of birth, menopausal status, postmenopausal hormone use, and time of day, month, and fasting status at blood draw

SS

22+ repeats

179

247

Age at menarche, parity, age at first birth, BMI at age 18 years, weight gain since age 8, benign breast disease, first degree family history, duration of postmenopausal hormone use; matched analysis

1.06 (0.83–1.35)

  

SL+LL

 

548

713

  

Suter, 2003 [69]

Cases (<45 years) identified through the Cancer Surveillance System of Western Washington and frequency-matched controls on 5-year age group and reference year

SS

22+ repeats

121

122

Age at reference and reference year

1.3 (0.9–1.8)

  

SL

 

255

206

 

1.2 (0.8–1.7)

  

LL

 

148

133

  
  1. 1S, short allele; L, long allele. 2Analyses using 29 and 30 repeats as the cut-point produced progressively higher significant risk estimates and progressively earlier age of onset, no trend test. 3Published odds ratio models the SS genotype as the high-risk allele. BMI, body mass index; CI, confidence interval; RR, relative risk.